Armed with mounds of patient data and a licensing deal with Genentech, Clover Therapeutics is ready to tackle the development of potential therapies for age-related ocular diseases.

Astellas Pharma Inc. plunked down nearly $109 million to snap up privately held Quethera Ltd. and the gene therapy company’s novel treatments for glaucoma and other ocular disorders.